Aethlon Medical Inc

NASDAQ:AEMDUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Contact Information

Headquarters

11555 Sorrento Valley Road, Suite 203SAN DIEGO, CA, United States 92121

Phone

619-941-0360

Fax

---

Executives

Independent Chairman of the Board

Edward Broenniman

Chief Executive Officer, Chief Financial Officer, Director

James Frakes

Chief Medical Officer

Steven Larosa

Independent Director

Nicolas Gikakis

Independent Director

Angela Rossetti